Clinicopathologic characteristics and correlation with CT antigen expression
| Characteristics . | No. patients per group . | Mean no. CT antigens expressed per patient (SD) . | P* . |
|---|---|---|---|
| Total | 55 | 2.4 (2.0) | |
| Age | .001 | ||
| 60 y or less | 22 | 1.2 (1.5) | |
| More than 60 y | 33 | 3.1 (2.0) | |
| Sex | .69 | ||
| Male | 38 | 2.4 (2.5) | |
| Female | 17 | 2.2 (2.0) | |
| Percentage of BM-infiltrating plasma cells | .17 | ||
| 10%-50% | 22 | 1.9 (1.8) | |
| 51%-100% | 33 | 2.7 (2.1) | |
| Heavy chain isotype | .07 | ||
| IgG | 24 | 1.6 (1.6) | |
| IgA | 16 | 2.7 (2.2) | |
| IgA + IgG | 1 | 5.0 (NA) | |
| IgM | 2 | 3.0 (0.0) | |
| Light chain | 10 | 2.4 (2.1) | |
| Light chain isotype | .29 | ||
| Kappa | 35 | 2.5 (2.1) | |
| Lambda | 18 | 1.7 (1.4) | |
| Stage, Durie-Salmon | .03 | ||
| I | 3 | 1.7 (0.6) | |
| II | 5 | 0.4 (0.9) | |
| III | 47 | 2.6 (2.1) | |
| Serum β2-microglobulin | .04 | ||
| Below 3.5 mg/L | 19 | 1.6 (1.5) | |
| 3.5 to 5.5 mg/L | 4 | 1.5 (1.3) | |
| Above 5.5 mg/L | 12 | 3.2 (2.1) | |
| Serum albumin | .99 | ||
| Below 3.5 g/dL | 20 | 2.4 (2.0) | |
| 3.5 g/dL or above | 21 | 2.4 (2.1) | |
| Serum LDH | .07 | ||
| 210 U/L or less | 36 | 1.9 (1.7) | |
| More than 210 U/L | 14 | 3.4 (2.7) | |
| Cytogenetics | .85 | ||
| Deletion 13q14 | 19 | 2.4 (2.1) | |
| No deletion 13q14 | 19 | 2.2 (1.8) | |
| Previous treatment | .78 | ||
| None | 5 | 3.0 (2.9) | |
| Chemotherapy alone | 30 | 2.3 (1.9) | |
| Autologous stem cell transplantation | 13 | 2.2 (2.0) | |
| Allogeneic stem cell transplantation | 7 | 2.4 (2.0) |
| Characteristics . | No. patients per group . | Mean no. CT antigens expressed per patient (SD) . | P* . |
|---|---|---|---|
| Total | 55 | 2.4 (2.0) | |
| Age | .001 | ||
| 60 y or less | 22 | 1.2 (1.5) | |
| More than 60 y | 33 | 3.1 (2.0) | |
| Sex | .69 | ||
| Male | 38 | 2.4 (2.5) | |
| Female | 17 | 2.2 (2.0) | |
| Percentage of BM-infiltrating plasma cells | .17 | ||
| 10%-50% | 22 | 1.9 (1.8) | |
| 51%-100% | 33 | 2.7 (2.1) | |
| Heavy chain isotype | .07 | ||
| IgG | 24 | 1.6 (1.6) | |
| IgA | 16 | 2.7 (2.2) | |
| IgA + IgG | 1 | 5.0 (NA) | |
| IgM | 2 | 3.0 (0.0) | |
| Light chain | 10 | 2.4 (2.1) | |
| Light chain isotype | .29 | ||
| Kappa | 35 | 2.5 (2.1) | |
| Lambda | 18 | 1.7 (1.4) | |
| Stage, Durie-Salmon | .03 | ||
| I | 3 | 1.7 (0.6) | |
| II | 5 | 0.4 (0.9) | |
| III | 47 | 2.6 (2.1) | |
| Serum β2-microglobulin | .04 | ||
| Below 3.5 mg/L | 19 | 1.6 (1.5) | |
| 3.5 to 5.5 mg/L | 4 | 1.5 (1.3) | |
| Above 5.5 mg/L | 12 | 3.2 (2.1) | |
| Serum albumin | .99 | ||
| Below 3.5 g/dL | 20 | 2.4 (2.0) | |
| 3.5 g/dL or above | 21 | 2.4 (2.1) | |
| Serum LDH | .07 | ||
| 210 U/L or less | 36 | 1.9 (1.7) | |
| More than 210 U/L | 14 | 3.4 (2.7) | |
| Cytogenetics | .85 | ||
| Deletion 13q14 | 19 | 2.4 (2.1) | |
| No deletion 13q14 | 19 | 2.2 (1.8) | |
| Previous treatment | .78 | ||
| None | 5 | 3.0 (2.9) | |
| Chemotherapy alone | 30 | 2.3 (1.9) | |
| Autologous stem cell transplantation | 13 | 2.2 (2.0) | |
| Allogeneic stem cell transplantation | 7 | 2.4 (2.0) |
A total of 55 patients with multiple myeloma were classified according to clinical features and cytogenetic characteristics of their disease. Information on the Ig isotype (N = 53), serum β2-microglobulin (N = 35), serum albumin (N = 43), and serum lactate dehydrogenase (LDH; N = 50) as well as for the cytogenetic results (N = 38) were available for fewer patients.
NA indicates not applicable.
P values represent results of a statistical analysis of correlations between numbers of CT antigens expressed and single clinicopathologic characteristics (Spearson rank correlation).